View in EDS HTML Full Text PDF Full Text

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

Saved in:
Bibliographic Details
Title: Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Authors: Bilgin, Burak1 (AUTHOR) drbbilgin@hotmail.com, Sendur, Mehmet Ali Nahit2 (AUTHOR), Yucel, Sebnem1 (AUTHOR), Celik, Emir3 (AUTHOR), Ozyukseler, Deniz Tataroglu4 (AUTHOR), Ayhan, Murat4 (AUTHOR), Basoglu, Tugba5 (AUTHOR), Ilhan, Aysegul6 (AUTHOR), Akdeniz, Nadiye7 (AUTHOR), Gulmez, Ahmet8 (AUTHOR), Dogan, Izzet9 (AUTHOR), Aktas, Burak Yasin10 (AUTHOR), Gurbuz, Mustafa11 (AUTHOR), Koca, Sinan12 (AUTHOR), Paydas, Semra13 (AUTHOR), Tatli, Ali Murat14 (AUTHOR), Cinkir, Havva Yesil15 (AUTHOR), Alan, Ozkan16 (AUTHOR), Erol, Cihan2 (AUTHOR), Hizal, Mutlu2 (AUTHOR)
Source: Journal of Cancer Research & Clinical Oncology. Jul2021, Vol. 147 Issue 7, p2145-2152. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:01715216
DOI:10.1007/s00432-020-03501-6